About Estrasorb

About Estrasorb^®

The only bio-identical estrogen in a soy-based lotion.

Estrasorb gives you all the benefits of estrogen, but because it is the only soy-based lotion, it is delivered differently from any other kind of estrogen therapy.

The estrogen in Estrasorb is bio-identical estradiol. That means it is the same as the estrogen your body makes naturally. Technically speaking, Estrasorb is an emulsion of tiny particles of estrogen and soybean oil. Once the Estrasorb lotion is rubbed on, the estradiol is absorbed into your skin and stays there.

Estrasorb is delivered directly to your bloodstream, bypassing the liver. This ensures a steady, consistent low dose of estrogen, without the ups and downs of pills and patches.

There are no preservatives and no alcohol in Estrasorb, and it is unscented. So it won’t dry your skin or interfere with any other fragrance you might want to wear.

Estrasorb is easy to use – just rub two packets, one on each leg, once a day. Estrasorb does the rest. It relieves your hot flashes, and leaves your skin feeling soft, smooth, and moisturized.

Proven to relieve hot flashes in women like you.

You may go through menopause naturally or because of surgery, and experience hot flashes either way. And you may try various treatments at any time, such as hormone therapy and lifestyle changes. No matter what stage you are in, you can turn to Estrasorb for the hot flash relief you need.

And the Good News- Estrasorb Really Works!

In studies, Estrasorb provided fast and effective relief of hot flashes, with 24-hour control.

The number of hot flashes per day was reduced by 85%, from 13 down to only 2 a day.

Almost all women – 91% – liked the feel of Estrasorb on their skin.

Estrasorb is safe and well tolerated, with a low incidence of side effects and very few skin reactions. Unlike patches, there is no sticky adhesive, gummy residue on the skin, or removal hassles.

Estrasorb is used to reduce moderate to severe hot flashes. To find out if Estrasorb is right for you, ask your doctor today.

Esprit Pharma Privacy Policy Terms of Use Press Releases Legal Statement Contact Us

ESTRASORB is indicated for the treatment of moderate to severe vasomotor symptoms associated with menopause. Estrasorb should not be used in women with any of the following conditions: undiagnosed abnormal genital bleeding; known, suspected, or history of cancer of the breast; known or suspected estrogen-dependent neoplasia; active deep-vein thrombosis, pulmonary embolism or history of these conditions; active or recent (eg, within the past year) arterial thromboembolic disease (eg, stroke, myocardial infarction); liver dysfunction or disease. ESTRASORB should not be used in patients with known hypersensitivity to its ingredients; known or suspected pregnancy. There is no indication for ESTRASORB in pregnancy. There appears to be little or no increased risk of birth defects in women who have used estrogens and progestins from oral contraceptives inadvertently during early pregnancy (see PRECAUTIONS in full Prescribing Information).

Estrogens increase the risk of endometrial cancer. Close clinical surveillance of all women taking estrogen is important. Adequate diagnostic measures, including endometrial sampling when indicated, should be undertaken to rule out malignancy in all cases of undiagnosed persistent or recurring abnormal vaginal bleeding. There is no evidence that the use of "natural" estrogens results in a different endometrial risk profile than synthetic estrogens at equivalent estrogenic doses. (see WARNINGS, Malignant neoplasms, Endometrial cancer).
Cardiovascular and other risks. Estrogens with or without progestins should not be used for the prevention of cardiovascular disease or dementia. (see WARNINGS, Cardiovascular disorders and Dementia).
The Women's Health Initiative (WHI) study reported increased risks of myocardial infarction, stroke, invasive breast cancer, pulmonary emboli, and deep vein thrombosis in postmenopausal women (50 to 79 years of age) during 5 years of treatment with oral conjugated estrogens (CE 0.625 mg) combined with medroxyprogesterone acetate (MPA 2.5 mg) relative to placebo (see CLINICAL PHARMACOLOGY, Clinical Studies, Warnings, Cardiovascular disorders and Malignant neoplasms, Breast cancer).
The Women's Health Initiative Memory Study (WHIMS), a substudy of WHI, reported increased risk of developing probable dementia in postmenopausal women 65 years of age or older during 4 years of treatment with oral conjugated estrogens plus medroxyprogesterone acetate relative to placebo.

It is unknown whether or not this finding applies to younger postmenopausal women. (See CLINICAL PHARMACOLOGY, Clinical Studies, Warnings, Dementia and PRECAUTIONS, Geriatric Use). Other doses of conjugated estrogens with medroxyprogesterone acetate, and other combinations of estrogens and progestins were not studied in the WHI and, in the absence of comparable data, these risks should be assumed to be similar. Because of these risks, estrogens with or without progestins should be prescribed at the lowest effective doses and for the shortest duration consistent with treatment goals and risks for the individual woman.